LRCXSell
Lam Research
Price (1y)
Recent regulatory events
- Auditor change (8-K Item 4.01)AnnotateView filing
Latest 8-K: 2025-09-11
Fair price check
5 different valuation methods each estimate what LRCX should be worth, then we compare to today's price.
- P/E multiplesOvervaluedthinks it's expensive — estimates $188.30, about 34% below today
- EV/EBITDAOvervaluedthinks it's expensive — estimates $148.59, about 48% below today
- P/B multiplesOvervaluedthinks it's expensive — estimates $82.23, about 71% below today
- Graham (defensive)Overvaluedthinks it's expensive — estimates $59.19, about 79% below today
- Residual IncomeOutlierestimate looks unreliable — estimates $34.73 — likely unreliable
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
| Method | Value |
|---|---|
| Graham (defensive) | $59.19 |
| P/E multiples(vs sector peers) | $188.30 |
| P/B multiples(vs sector peers) | $82.23 |
| EV/EBITDA(vs sector peers) | $148.59 |
| Residual Income | $34.73 |
| DCF (2-stage) | skipped |
- extreme rim estimate
Median of all applicable methods (current price $284.72). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Pillar breakdown
8 dimensions, each scored 0–100 against the universe
- QualityProfit margins & asset efficiency85Strong
- ValuePrice vs fundamentals21Poor
- GrowthRevenue & earnings trajectory41Weak
- MomentumRecent price strength92Strong
- HealthBalance sheet & solvency85Strong
- ProfitabilityROE, ROA, ROIC76Strong
- TechnicalTrend & volatility signals66Decent
- RiskVolatility & drawdown profile53Decent
Pillars not shown: Sentiment, ML (Phase 5+).
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $356.06B |
| Revenue (TTM) | $21.68B |
| Net income (TTM) | $6.71B |
| Operating cash flow (TTM) | $6.95B |
| CapEx (TTM) | $949.79M |
| Free cash flow (TTM)CFO − CapEx | $6.00B |
| Total assets | $20.79B |
| Total liabilities | $10.21B |
| Stockholders' equity | $10.58B |
| Cash & equivalents | $4.75B |
| Shares outstanding | 1.25B |
| EPS (basic) | $3.97 |
| EPS (diluted) | $3.95 |
| P/E ratio (TTM) | 53.08 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-04-23
- Latest period end
- 2026-04-21
- Filing lag
- 23 days
- Missing metrics
- none
Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.